IMRICOR ACHEIVES MAJOR MILESTONE WITH NORTHSTAR

17 October 2024 – Melbourne, Australia (**16 August 2024** – Minneapolis, MN United States) – **Imricor Medical Systems, Inc.** (**Company** or **Imricor**) (**ASX: IMR**) provides the following update regarding the Company's NorthStar 3D mapping system.

As first announced on 13 April 2024, Imricor is a member of the *Sensing and Image-Guided Neurological therapies, cardiac Electrophysiology and Tumour treatments* (SIGNET) consortium, along with Philips Medical Systems (Philips) and others. An overview of SIGNET can be found here: https://itea4.org/project/signet.html.

Imricor's SIGNET involvement is the mechanism through which the Company and Philips have collaborated to develop the software necessary for Imricor's NorthStar 3D mapping system to operate with the Philips MRI platform.

The Company is pleased to announce that all technical goals of SIGNET related to NorthStar operating on the Philips MRI platform were achieved during extensive testing performed over fourteen hours at Amsterdam University Medical Centre on October 10th. Imricor and Philips are now working on full commercialization efforts for NorthStar on the Philips platform.

Imricor's Chair and CEO, Steve Wedan, commented: "We already expect NorthStar to be commercially available next year for use with the Siemens MRI platform. Upon the completion of this SIGNET milestone, we now have a clear path to commercialisation on the Philips MRI platform as well. In addition, we continue to make progress with GE Healthcare to deliver NorthStar on the GE MRI platform, and we hope to report on that effort soon.

"NorthStar is highly significant for Imricor in many ways. Not only does it enhance procedures for doctors, it also provides ongoing licensing revenue to the business which builds on the consumable device revenue we generate with each procedure."



Imricor's NorthStar 3D Mapping and Guidance System

Signet Project Description

The overall objective of SIGNET is to develop efficient image-guided treatment workflows to replace currently complex procedures in cardiology, oncology and neurology. We develop systems and technologies, AI-enabled products and solutions, necessary to ultimately realize the North Star of single-episode, personalized, dose-adaptive, high-precision Magnetic Resonance guided treatments and interventions. These technologies and solutions aim to improve patient comfort, safety, treatment outcome, staff availability and economic viability. We focus on use cases where alternative image guidance approaches are either not feasible or where the value of direct MR visualization is obvious.

ENDS
Authorised for release by Steve Wedan, Executive Chair, President, and CEO

Media and Investor Relations Contacts:

Simon Hinsley
Executive Director, NWR
simon@nwrcommunications.com.au
+61 401 909 653

Nick Corkill
VP Corporate Strategy, Imricor
nick.corkill@imricor.com
+61 450 475 633

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is a leading developer of innovative MRI-compatible medical devices which can be used to carry out real-time iCMR cardiac ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac ablation procedures.

Imricor's Products

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company's prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union, the Kingdom of Saudi Arabia (KSA), and New Zealand with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also pursuing the required regulatory approvals to place its key products on the market in the U.S. and the other Middle East countries.

The Company has also obtained approval within the EU and KSA for the sale of the Advantage-MR EP Recorder/Stimulator System and other consumable products, such as the Vision-MR Diagnostic Catheter (pending in KSA) and Vision-MR Dispersive Electrode.

Imricor sells its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V., Siemens Healthcare GmbH, and GE HealthCare help to target certain sites and support the design and construction of iCMR labs for those sites.

Foreign Ownership Restrictions

Imricor's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU. sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements

because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.